Description:
The purpose of this study is to test the safety of a new method to treat Diffuse Intrinsic
Pontine Glioma (DIPG). The researchers will use "convection-enhanced delivery" (CED) to
deliver an agent called 124I-omburtamab. CED is performed during surgery. The study agent is
infused through a small tube placed into the tumor in the brain. Many studies have shown this
can safely be done in animals but this study is the first time 124I-omburtamab will be given
by CED in humans. This will be one of the first times that CED has been performed in the
brain stem.
Omburtamab is something called an antibody. Antibodies are made by the body to fight
infections and sometimes cancer. The antibody omburtamab is produced by mice and can attack
many kinds of tumors. A radioactive substance, 124I-omburtamab, is attached to omburtamab.
124I-omburtamab sticks to parts of tumor cells and can cause the tumor cells to die from
radiation. Studies have also been done on humans using 124I-omburtamab to treat other kinds
of cancer. Our studies of some DPG and related tumors suggest that omburtamab will bind to
the tumor, but the investigators don't know that for sure.
In this study, the researchers want to find out how safe 124I-omburtamab given by CED is at
different dose levels. They will look to see what effects (both good and bad) it has on the
patient. The dose of 124I-omburtamab will increase for each new group of patients. The
procedure has already been safely performed with lower doses and infusion volumes in a number
of patients here at MSKCC. The amount they get will depend on when they enter the study. If
too many serious side effects are seen with a certain dose, no one will be treated with a
higher dose, and some more patients may be treated with a lower dose to make sure that dose
is safe.
Title
- Brief Title: Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
- Official Title: A Phase I Study of Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
Clinical Trial IDs
- ORG STUDY ID:
11-011
- NCT ID:
NCT01502917
Conditions
- Brain Cancer
- Brain Stem Glioma
Interventions
Drug | Synonyms | Arms |
---|
Radioactive iodine-labeled monoclonal antibody omburtamab | | Radioactive iodine-labeled monoclonal antibody omburtamab |
Purpose
The purpose of this study is to test the safety of a new method to treat Diffuse Intrinsic
Pontine Glioma (DIPG). The researchers will use "convection-enhanced delivery" (CED) to
deliver an agent called 124I-omburtamab. CED is performed during surgery. The study agent is
infused through a small tube placed into the tumor in the brain. Many studies have shown this
can safely be done in animals but this study is the first time 124I-omburtamab will be given
by CED in humans. This will be one of the first times that CED has been performed in the
brain stem.
Omburtamab is something called an antibody. Antibodies are made by the body to fight
infections and sometimes cancer. The antibody omburtamab is produced by mice and can attack
many kinds of tumors. A radioactive substance, 124I-omburtamab, is attached to omburtamab.
124I-omburtamab sticks to parts of tumor cells and can cause the tumor cells to die from
radiation. Studies have also been done on humans using 124I-omburtamab to treat other kinds
of cancer. Our studies of some DPG and related tumors suggest that omburtamab will bind to
the tumor, but the investigators don't know that for sure.
In this study, the researchers want to find out how safe 124I-omburtamab given by CED is at
different dose levels. They will look to see what effects (both good and bad) it has on the
patient. The dose of 124I-omburtamab will increase for each new group of patients. The
procedure has already been safely performed with lower doses and infusion volumes in a number
of patients here at MSKCC. The amount they get will depend on when they enter the study. If
too many serious side effects are seen with a certain dose, no one will be treated with a
higher dose, and some more patients may be treated with a lower dose to make sure that dose
is safe.
Trial Arms
Name | Type | Description | Interventions |
---|
Radioactive iodine-labeled monoclonal antibody omburtamab | Experimental | This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma. | - Radioactive iodine-labeled monoclonal antibody omburtamab
|
Eligibility Criteria
Inclusion Criteria:
- Consensus of diagnosis must be reached by a multidisciplinary pediatric neuro-oncology
team by considering both clinical evidence and MRI presentation. Tissue diagnosis is
not required.
- The patient must have undergone prior external beam radiotherapy to a dose of 54-60 Gy
to the brain stem. At least 4 weeks but no more than 14 weeks must have elapsed from
the completion of radiotherapy.
- The patient must be in adequate general condition for study, with Lansky or Karnofsky
Performance Score of ≥ 50 at study entry .
Lansky Performance scale will be used for patients ≤16 years of age.
- The patient must be ≥ 2 and ≤ 21 years old.
- Patient must weigh a minimum of 8 kg.
Exclusion Criteria:
- Clinical and/or radiographic (MRI) progression of tumor following external beam
radiation therapy.
- Metastatic disease.
- Untreated symptomatic hydrocephalus determined by treating physician.
- AST or ALT > 2x the upper limit of normal.
- Platelets < 100,000/mcL.
- ANC < 1000/mcL.
- Abnormal PT (Inr) >1.5 INR or PTT > 42 sec (may be corrected with FFP,
cryoprecipitate, vitamin K, etc).
- Total bilirubin > 2.0 mg/dl.
- Serum creatinine > 1.5x the upper limit of normal for age, or calculated creatinine
clearance or nuclear GFR < 70 ml/min/1.73 m2.
Maximum Eligible Age: | 21 Years |
Minimum Eligible Age: | 2 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | maximum tolerated dose |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Determination that a dose is safe will be made following the treatment of at least 3 but no more than 6 patients at a particular dose level. The dose levels are DL1 (0.25 mCi), DL2 (0.5 mCi), DL3 (0.75 mCi), DL4 (1.0 mCi) DL5 (2.5mCi), DL6 (3.25mCi), DL7 (4.0mCi), DL 7.1(4.0mCi), DL 7.2 (4.0mCi), DL 8 (6.0mCi), DL 9 (8.0mCi), DL 10 (10.0mCi), DL 11 (12.0mCi) ,fallback DL0 (0.125 mCi) FB1 (1.50mCi) and FB2 (2.0mCi). An incidence of dose-limiting toxicity (DLT) in the range of 25% is considered acceptable in this population. A maximum tolerated dose (MTD) will be defined as the dose level below that at which 2 DLTs have occurred. |
Secondary Outcome Measures
Measure: | overall survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Overall survival from the time of diagnosis will be recorded for every patient in this study. Overall survival will be estimated by Kaplan-Meier methodology. |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Y-mAbs Therapeutics |
Trial Keywords
- Brain stem glioma
- CNS
- MAB 124I-omburtamab
- infusion cannula
- DIPG
- Diffuse Intrinsic Pontine Glioma
- 11-011
Last Updated
June 11, 2021